DK0699199T3 - Heteroatomsubstituerede alkylbenzylaminoquinuclidiner som substans P-antagonister - Google Patents

Heteroatomsubstituerede alkylbenzylaminoquinuclidiner som substans P-antagonister

Info

Publication number
DK0699199T3
DK0699199T3 DK94914619T DK94914619T DK0699199T3 DK 0699199 T3 DK0699199 T3 DK 0699199T3 DK 94914619 T DK94914619 T DK 94914619T DK 94914619 T DK94914619 T DK 94914619T DK 0699199 T3 DK0699199 T3 DK 0699199T3
Authority
DK
Denmark
Prior art keywords
alkyl
alkoxy
pct
hydrogen
independently
Prior art date
Application number
DK94914619T
Other languages
Danish (da)
English (en)
Inventor
Kunio Satake
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0699199T3 publication Critical patent/DK0699199T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DK94914619T 1993-05-19 1994-05-13 Heteroatomsubstituerede alkylbenzylaminoquinuclidiner som substans P-antagonister DK0699199T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11710293 1993-05-19
PCT/JP1994/000781 WO1994026740A1 (fr) 1993-05-19 1994-05-13 Alkyle benzylaminoquinuclidines a substitution heteroatomique utilisees comme antagonistes de substances p

Publications (1)

Publication Number Publication Date
DK0699199T3 true DK0699199T3 (da) 2002-12-16

Family

ID=14703456

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94914619T DK0699199T3 (da) 1993-05-19 1994-05-13 Heteroatomsubstituerede alkylbenzylaminoquinuclidiner som substans P-antagonister

Country Status (12)

Country Link
US (1) US5741797A (fr)
EP (1) EP0699199B1 (fr)
AT (1) ATE228129T1 (fr)
AU (1) AU6691094A (fr)
CA (1) CA2161886C (fr)
DE (1) DE69431751T2 (fr)
DK (1) DK0699199T3 (fr)
ES (1) ES2184762T3 (fr)
FI (1) FI942314A (fr)
IL (1) IL109646A0 (fr)
PT (1) PT699199E (fr)
WO (1) WO1994026740A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2205016A1 (fr) * 1994-11-10 1996-05-23 Hans-Jurgen Ernst Hess Antagonistes du recepteur nk-1 destines au traitement de troubles oculaires
DE69623580T2 (de) 1995-12-21 2003-01-09 Pfizer 3-((5-Substituierte Benzyl)Amino)-2-Phenylpiperidine als Substance-P-Antagonisten
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
PL367944A1 (en) * 2001-07-20 2005-03-07 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
AU2003243353A1 (en) * 2002-05-29 2003-12-19 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
EP1904069B1 (fr) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
CA2664113C (fr) 2006-09-22 2013-05-28 Merck & Co., Inc. Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
CA2682727C (fr) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Derive d'indoledione
EP2170076B1 (fr) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
CA2760837C (fr) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et son utilisation
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CA2805265A1 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian)
WO2012024170A2 (fr) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (fr) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833668A4 (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
HUT65771A (en) * 1991-05-22 1994-07-28 Pfizer Process for producing substituted 3-amino-quinuclidine derivatives and pharmaceutical compositions containing them
UA27776C2 (uk) * 1991-05-31 2000-10-16 Пфайзер Інк. Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
KR0154882B1 (ko) * 1991-06-20 1998-11-16 알렌 제이. 스피겔 질소 함유 헤테로사이클릭 화합물의 플루오로알콕시벤질아미노 유도체
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
US5294744A (en) * 1993-04-20 1994-03-15 Pfizer Inc. Formylation process for aromatic aldehydes
JP3326489B2 (ja) * 1996-02-10 2002-09-24 好高 青山 部品供給ロッド装置とそれによる供給方法
JPH09221677A (ja) * 1996-02-14 1997-08-26 Kansai Coke & Chem Co Ltd 石炭の高温予熱方法
JPH09319064A (ja) * 1996-05-29 1997-12-12 Konica Corp 写真製品の生産方法及び生産装置

Also Published As

Publication number Publication date
CA2161886A1 (fr) 1994-11-24
FI942314A (fi) 1994-11-20
ES2184762T3 (es) 2003-04-16
FI942314A0 (fi) 1994-05-18
ATE228129T1 (de) 2002-12-15
IL109646A0 (en) 1994-08-26
EP0699199A1 (fr) 1996-03-06
WO1994026740A1 (fr) 1994-11-24
CA2161886C (fr) 1999-12-07
EP0699199B1 (fr) 2002-11-20
DE69431751D1 (de) 2003-01-02
US5741797A (en) 1998-04-21
DE69431751T2 (de) 2003-04-03
AU6691094A (en) 1994-12-12
PT699199E (pt) 2003-01-31

Similar Documents

Publication Publication Date Title
DK0699199T3 (da) Heteroatomsubstituerede alkylbenzylaminoquinuclidiner som substans P-antagonister
FI944394A (fi) Kinuklidiinijohdannaisia P-aineen antagonisteina
PT98393A (pt) Processo para a preparacao de derivados de quinuclidina
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
MX9207335A (es) Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene.
ES2169760T3 (es) Pirazoles sustituidos en 3,4 para el tratamiento de la inflamacion.
MY102027A (en) Leukotriene antagonists
DE60107435D1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
MY116761A (en) Novel spiroazabicyclic heterocyclic compounds.
SE8301412D0 (sv) Substituerade 1h-pyrazolo(1,5)pyrimidiner och forfarande for deras framstellning
ES2063309T3 (es) Derivados de pirimidina 3-oxido halogenados, su utilizacion para el tratamiento y la prevencion de la caida de los cabellos y para estimular su crecimiento.
ES493922A0 (es) Procedimiento para la preparacion de 4-fenoxipiperidinas
SE7706346L (sv) Bensaminderivat
PT83345B (pt) Processo para a preparacao de gama-carbolinas antipsicoticas
MX9709465A (es) Derivados de bencimidazol 2-sustituidos como inhibidores de la proliferacion de celulas del musculo liso.
ES2182509T3 (es) Derivados de n-ariloxietilamina para el tratamiento de la depresion.
YU68502A (sh) Piridazinil fenil hidrazoni korisni protiv kongestivnog srčanog udara
GR78456B (fr)
DK333380A (da) Fremgangsmaade til fremstilling af 3-amino-1-benzoxepin-derivater eller syreadditionssalte deraf
DK356287D0 (da) 2,6-piperazindionderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
DE69414117D1 (de) 1,5-benzodiazepin-derivate verwendbar als cck oder gastrin antagonisten
DK0514267T3 (da) Hidtil ukendte amidderivater af 1-aminooctahydropyrido(2,1-c)(1,4)oxazin, fremgangsmåder til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES431300A1 (es) Un procedimiento de preparacion de un derivado de benzoxa- zol.
MX9709650A (es) Derivados de bencimidazol 2-sustituidos como inhibidores de proliferacion de celulas de musculo liso.